RxDoctor Payments Data

Santina Carminati Taddei, MD

Rheumatology · Mesa, AZNPI 1861494551

Payments from drug & device makers

$2,310in general payments, 2019–2025

Across 82 payments — averaging $28.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$765
  • AbbVie$602
  • Amgen$418
  • Pfizer$136
  • Lilly USA, LLC$93
  • Radius Health, Inc.$84
  • plus $212 from 8 others

What the payments were for

  • Consulting fees$56024%
  • Food & beverage$1,75076%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,310 in reported general payments places this provider in the 35th percentile of 102 rheumatology providers in Arizona.

See all rheumatology providers in Arizona

Medicare billing

Part B allowed, 2024
$8,396
Medicare patients
27
Services billed
84

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab57$416,447
Enbrel SureclickEtanercept30$213,494
Cosentyx Sensoready (2 Pens)Secukinumab17$116,191
Cimzia (2 Pack)Certolizumab Pegol16$96,702
RinvoqUpadacitinib13$78,482
Xeljanz XrTofacitinib Citrate14$75,758
Hydroxychloroquine Sulfate101$1,944
MethotrexateMethotrexate Sodium115$1,393
Colchicine14$854
Prednisone134$810
Leflunomide22$575
Mycophenolate Mofetil11$494
Allopurinol40$398
Methotrexate SodiumMethotrexate Sodium/Pf15$182
Folic Acid11$72

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$602$78,48213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 102 rheumatology providers in Arizona.

Other rheumatology in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →